Oral Niacinamide for Actinic Keratosis Prevention
Oral nicotinamide 500 mg twice daily reduces actinic keratoses in immunocompetent patients with multiple AKs, but this benefit is NOT supported by current guidelines and does NOT extend to immunosuppressed transplant recipients.
Evidence in Immunocompetent Patients
The landmark ONTRAC trial demonstrated that oral nicotinamide 500 mg twice daily for 12 months significantly reduced actinic keratoses in high-risk immunocompetent patients 1:
- AK counts were reduced by 11% at 3 months, 14% at 6 months, 20% at 9 months, and 13% at 12 months compared to placebo (all P ≤ 0.01) 1
- The treatment also reduced new non-melanoma skin cancers by 23% during the intervention period 1
- Importantly, the benefit disappeared after discontinuation - there was no evidence of sustained effect once nicotinamide was stopped 1
- The safety profile was excellent with no noteworthy differences in adverse events between groups 1
A small case-control study in transplant recipients showed 88% of patients had decreased AK size after 6 months of nicotinamide 500 mg daily, with 42% achieving complete clinical regression 2. However, this study had significant methodological limitations.
Evidence in Immunosuppressed Patients
The evidence clearly shows nicotinamide does NOT work in organ transplant recipients:
- The ONTRANS trial in 158 transplant recipients found no reduction in keratinocyte cancers (rate ratio 1.0; 95% CI 0.8-1.3; P=0.96) with nicotinamide 500 mg twice daily for 12 months 3
- No significant differences were observed in squamous-cell carcinoma counts, basal-cell carcinoma counts, or actinic keratosis counts 3
- A U.S. pilot trial in kidney transplant recipients similarly found no benefit, with 40% attrition in the nicotinamide arm due to tolerability issues 4
Guideline Recommendations
Current major dermatology guidelines do NOT recommend nicotinamide for AK prevention:
- The 2017 British Association of Dermatologists guidelines for AK management make no mention of nicotinamide as a preventive or treatment option 5
- The 2021 and 2022 American Academy of Dermatology guidelines for AK management do not include nicotinamide in their treatment recommendations 6, 7
- The 2018 AAD guidelines for basal cell carcinoma state there is insufficient evidence to make a recommendation on oral nicotinamide for BCC chemoprevention 8
- The 2018 AAD guidelines for cutaneous squamous cell carcinoma note early evidence but do not make a formal recommendation 9
- The 2024 European consensus guideline for AK does not recommend nicotinamide 10
Meta-Analysis Findings
A 2023 systematic review and meta-analysis pooling immunocompetent and immunosuppressed patients found no significant association between nicotinamide and reduced risk of squamous cell carcinoma (RR 0.81,95% CI 0.48-1.37), basal cell carcinoma (RR 0.88,95% CI 0.50-1.55), or NMSC overall (RR 0.82,95% CI 0.61-1.12) 11.
Clinical Implications
For immunocompetent patients with multiple AKs:
- Nicotinamide 500 mg twice daily may reduce AK burden during active treatment 1
- However, this is not a guideline-recommended approach - standard field treatments (5-fluorouracil, imiquimod, photodynamic therapy) remain first-line 7
- The benefit requires continuous treatment; stopping results in loss of effect 1
- Consider only as an adjunctive measure in highly motivated patients who understand the need for indefinite therapy
For immunosuppressed transplant recipients:
- Do not use nicotinamide for AK prevention - the evidence clearly shows no benefit 3, 4
- Focus on guideline-recommended approaches: rigorous sun protection, regular surveillance, and aggressive treatment of existing lesions 5
Important Caveats
- The FDA labeling for topical niacinamide relates to sunscreen products, not oral supplementation for AK prevention 12
- Tolerability issues (particularly gastrointestinal symptoms) can limit adherence, especially at higher doses 4
- The mechanism requires continuous NAD+ repletion to support DNA repair and reduce UV-induced immunosuppression 1